MAP2K1 and leukemia: Some examples include the combined effects that induce fatality of leukemia cells [66], attenuate tumor growth of BRAF-mutated colorectal cells [67], and enhance the antitumor effects of MEK1/2 treatment in RAS-mutated lung cells [68].